Oxford University Receives $12.3M to Study Medical Cannabis
One of the world’s top research universities, Oxford University, has received 10 million pounds ($12.3 million) from a London-based private equity firm to study the medical benefits of marijuana, a move that could lead to more acceptance of MMJ as a medicinal therapy worldwide.
According to a news release, Oxford will use the money to identify state-of-the-art medical therapy by researching the “molecular, cellular and system mechanisms of cannabinoids.”
Citing pain, cancer and inflammatory disease, the release noted the British university will target therapies for acute and chronic conditions.
Kingsley Capital Partners, which is providing the funding, has plowed investment dollars into the therapeutic cannabinoid market.
Kingsley plans to bankroll Oxford’s research effort through a new portfolio company, Oxford Cannabinoid Technologies. The program is funded over 36 months.
Oxford and Kingsley plan to host an International Cannabinoid Biomedicine Conference intended “to increase dialogue in the cannabinoid research space.” The first gathering is scheduled for the fourth quarter of 2017.
This article first appeared on Marijuana Business Daily.
Patients often substitute medical marijuana for opioid pain medications and other drugs
Medical marijuana patients tend to reduce their use of prescription opioid pain medications, accordi…
Cannabinoids used in Sequence with Chemotherapy are a more Effective Treatment for Cancer
New research has confirmed that cannabinoids - the active chemicals in cannabis - are effective in k…
Cannabis Extracts Associated With Reduced ADHD Symptoms
The administration of whole-plant cannabis extracts is associated with improvements in cognition and…
Veteran Says Medical Marijuana Controls His PTSD Symptoms: Wants Cannabis For All Vets
Some of the latest statistics show that somewhere around 20 percent of the military veterans that se…
Cannabidiol reverses the mCPP-induced increase in marble-burying behavior
Cannabidiol (CBD), one of the main components of Cannabis sp., presents clinical and preclinical anx…
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported to act as…